Skip to navigation Skip to content



Positive Results Reported from a Phase 2 Trial of Stem Cell Therapy

December 23, 2020

A team from Israel’s Hadassah University Hospital has published results from a phase 2 clinical trial of mesenchymal stem cell therapy in active, progressive MS. “Mesenchymal stem cells” are adult stem cells found in several places in the body, including the bone marrow, skin and fat tissue. Participants were 48 people with progressive MS with moderate to more severe disability.

There were three study groups. One group was treated with cells administered into the vein (intravenous), one group was administered cells into the spinal fluid (intrathecal), and one group received sham treatment. After 6 months, those on sham treatment received active cells, and the other groups received a second dose of active cells or sham treatment. All participants were monitored with various measures to try to detect a benefit and safety, and to find the best route for administering these cells. The cells appeared to be well tolerated, with no serious adverse events linked to treatment.

Significantly fewer participants experienced disability progression in the treatment groups compared with the sham group. Several measures, including relapse rate, improved significantly more in the intrathecal group.  The authors suggest that a phase 3 trial is warranted to further test the safety and effectiveness of this therapy in larger numbers of people with MS.

“Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis,” by Panayiota Petrou, Ibrahim Kassis, Netta Levin, Friedemann Paul, Yael Backner, Tal Benoliel, Frederike Cosima Oertel, Michael Scheel, Michelle Hallimi, Nour Yaghmour, Tamir Ben Hur, Ariel Ginzberg, Yarden Levy, Oded Abramsky, and Dimitrios Karussis, was published November 30, 2020 in the journal Brain.

Read more from Hadassah

Read about more mesenchymal stem cell studies

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.